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Abstract 
Background: Hemolytic uremic syndrome (HUS) is a rare condition which diagnosed with the triad of thrombocyto-
penia, microangiopathic hemolytic anemia, and acute renal injury. There is a high requirement for research to discover 
treatments. HUS registries can be used as an important information infrastructure. In this study, we identified and 
compared the different features of HUS registries to present a guide for the development and implementation of HUS 
registries.
Results: The purposes of registries were classified as clinical (9 registries), research (7 registries), and epidemiological 
(5 registries), and only 3 registries pursued all three types of purposes. The data set included demographic data, medi-
cal and family history, para-clinical and diagnostic measures, treatment and pharmacological data, complications, 
and outcomes. The assessment strategies of data quality included monthly evaluation and data audit, the participa-
tion of physicians to collect data, editing and correcting data errors, increasing the rate of data completion, following 
guidelines and data quality training, using specific data quality indicators, and real-time evaluation of data at the time 
of data entry. 8 registries include atypical HUS patients, and 7 registries include all patients regardless of age. Only two 
registries focused on children. 4 registries apply prospective and 4 applied both prospective, and retrospective data 
collection. Finally, specialized hospitals were the main data source for these registries.
Conclusion: Based on the findings, we suggested a learning framework for developing and implementing an HUS 
registry. This framework includes lessons learned and suggestions for HUS registry purposes, minimum data set, data 
quality assurance, data collection methods, inclusion and exclusion criteria as well as data sources. This framework can 
help researchers develop HUS registries.
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Background
Hemolytic uremic syndrome (HUS) is a clinical condition 
characterized by thrombocytopenia, thrombotic micro-
angiopathy (TMA), and acute kidney injury [1]. The typi-
cal infectious cause of HUS is Escherichia coli (E. coli), 
producing Shiga toxin (typical, or STEC-HUS). However, 
patients sometimes should be screened for genetic causes 
or underlying diseases [2]. Diarrhea, vomiting, renal 
injury symptoms, and extrarenal manifestations (20% 
of cases) such as seizures are symptoms of the disease 
[3]. Atypical HUS (aHUS) is also caused by the uncon-
trolled activation of complement factors (a part of the 
immune system) [4], and is very chronic and progressive 
and eventually leads to kidney (or other systemic organs) 
injuries [5]. A wide range of therapies was suggested 
from conservative management to plasma exchange 
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(PEX), and using Eculizumab (Ecu) [6]. A recent system-
atic review reports that the annual incidence of aHUS for 
all ages is 0.23 to 1.9 per 1 million people and 0.26 to 0.75 
for patients at the age of 20 years old or less [7]. HUS is 
one of the various forms of TMA [8], and with symptoms 
such as thrombocytopenia, nonimmune microangio-
pathic hemolytic anemia, microvascular occlusion, and 
acute kidney injury, it is in the group of diseases known 
as TMAs [9].
HUS is a rare condition [10] which its clinical pattern 
can occur in a wide range of clinical scenarios [3]. Rare 
diseases are characterized by the large number and broad 
diversity of disorders and symptoms that are often incur-
able [11] that reduce the quality of life and increase mor-
tality [12, 13]. Therefore, due to variations in the course 
of rare diseases, low prevalence, and other complications, 
there is a large gap between basic research in this field 
and the need to discover new therapies and drugs for rare 
diseases [14].
The development of a disease registry can help provide 
research opportunities and solve issues related to scien-
tific studies in this field. Disease registry programs are 
organized systems which collect uniform data and eval-
uate the outcomes of a specific disease in a pre-defined 
population [15]. Therefore, registries facilitate research, 
especially in the rare disease domain. These systems can 
be used for patients’ recruitment for clinical trials, sup-
port health care management, and improve patient care 
[16].
Implementation of Rare Disease Registries (RDRs) 
helps scientists understand the variations about this type 
of disease and provides the necessary information for 
designing clinical trials. The population of patients with 
a rare disease is often small and geographically dispersed 
[17]. In this regard, RDRs enhance the quality and effi-
ciency of clinical studies by providing more samples [18]. 
In addition to increasing knowledge about rare diseases, 
RDRs are an important source of data on drug safety and 
efficacy for post-market surveillance [17, 19].
Due to the importance of this type of disease registry, 
many countries have implemented HUS registries, each 
of which has its features [4, 20]. Despite designing differ-
ent HUS registries and considering that there is no stand-
ard guide in the world on how to develop these types of 
registries [21], we identified and compared the different 
features of HUS registries and their similarities and dif-
ferences to learn lessons regarding the features of HUS 
registries and to develop a guideline to design and imple-
ment an HUS registry.
Method
The features of HUS registries in countries were identi-
fied by descriptive and comparative methods. The RDRs 
can be usually described from different aspects [22], and 
due to the available information; we considered the fol-
lowing aspects:
1. Purposes: Registries can be developed for different 
purposes [19] which can range from monitoring, 
control, and management of a disease to identify dis-
ease course and outcomes, as well as to evaluate the 
safety and effectiveness of interventions and treat-
ments [23].
2. Inclusion and exclusion criteria: The registry team 
should determine the inclusion criteria, and indeed 
the eligibility of patients for registration. On the 
other hand, exclusion criteria exclude individuals 
from entering the registry [22, 23].
3. Minimum Data Set (MDS): Another important fea-
ture of registries is determining the specified MDS, 
which includes a group of disease-related data ele-
ments to be collected [24].
4. Data sources which are the settings and organiza-
tions from where the information is collected [22].
5. Determining data collection method which may 
include interviewing patients, reviewing health 
records of the patients, or direct clinical observation 
[25].
6. Data quality control is one of the activities which 
should be continuously done to assure and increase 
data quality [26–28].
7. Registrars: One of the necessities to  make sure the 
correct data entry is to determine the relevant reg-
istrars. Registrars collect data and enter it into the 
registry system during their work or dedicated work 
[29].
This study was conducted to determine the compre-
hensive dimensions of features considered in the present 
HUS registries to achieve a learning framework for the 
optimal and effective implementation of HUS registries.
Selection of HUS registries
In December 2020, we first searched the recognized HUS 
and TMA registries on the European Orphanet website 
and the registry official websites. To consider publications 
related to these registries, we also searched electronic 
databases, including ISI Web of sciences, Embase, Pub-
Med (Medline), Scopus, and Google search engine. The 
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terms "Hemolytic uremic syndrome/thrombotic micro-
angiopathy registry" and "hemolytic uremic syndrome/
thrombotic microangiopathy database" were used. The 
articles which described the features of HUS registries 
were considered. To collect data regarding some of these 
registries, we corresponded with their managers.
We considered specific registries for HUS (typical or 
atypical) or TMA registries with HUS inclusion criteria. 
The other inclusion criterion was the availability of infor-
mation regarding the aspects of interest. After reviewing 
the registry and article titles, and our inclusion criteria (if 
any), 41 registries were identified, of which only 14 were 
related to HUS or TMA. Among them, 10 registries were 
finally selected. Other 4 registries were excluded because 
we could not find related information or these registries 
were a participant of global aHUS registry [30]. Six of 10 
selected registries were identified from Orphanet and the 
others from articles and websites. Three registries related 
to TMA [31–33] due to the inclusion of patients with 
HUS were also selected (Table 1).
Data collection and analysis
We reviewed the relevant articles and websites and also 
communicated with the managers of selected registries 
by email to collect information for the features of these 
registries. We developed comparative tables (Additional 
file  1) to thematically compare these features and iden-
tify similarities and differences, and make suggestions to 
implement these registries.
Results
We finally selected 10 HUS registry programs (Table 1). 
In the following section, their support centers or super-
visors are introduced. Furthermore, the details of these 
registries are provided in Additional file 1.
These registries are introduced as follows. We used 
these registry numbers to refer to the name of these reg-
istries in the following sections.
Registry 1: Oklahoma TTP-HUS Registry is one of 
the oldest local registry systems set up at the Oklahoma 
Blood Institute and under the supervision of the Univer-
sity of Oklahoma Health Sciences Center to register any 
patient for whom PEX is requested [35].
Registry 2: International Registry of recurrent and 
familial HUS/thrombotic thrombocytopenic purpura 
(TTP) is also a global disease registry system set up with 
Mario Negri Institute of Pharmacological Research’s sup-
port and supervision at the Clinical Research Center for 
Rare Diseases in Italy [39].
Registry 3: French registry of aHUS in children was 
launched as a hospital clinical research program at the 
Laboratory of Biological Immunology at the European 
Hospital Georges Pompidou under the supervision and 
support of the Association for Information and Research 
on Genetic Renal Diseases, France [40].
Registry 4: Italian registry of HUS is a national registry 
in Italy that the National Institute of Health has imple-
mented as part of the activities of the Italian Society for 
Pediatric Nephrology [41, 42].
Registry 5: International registry and biorepository for 
TMA was supported by Northwell Health Clinical Inte-
gration Network (New York state health service provider) 
for clinical research on diseases in TMA group such as 
HUS [31, 43].
Registry 6: TTP/TMAs registry was set up by the 
Department of Epidemiology and Preventive Medicine at 
Monash University in Australia to establish a high-quality 
clinical and specialized registry to support research [32].
Registry 7: German STEC-HUS registry, implemented 
by the German Society of Nephrology, is based on a 
Table 1. 10 selected HUS registries
*From Orphanet
aHUS: Atypical Hemolytic Uremic Syndrome; HUS: Hemolytic Uremic Syndrome; NA: Not Available information; Reg.: Registry; STEC-HUS: Shiga toxin-producing E. coli 
HUS; TMA: Thrombotic Microangiopathy; TTP: Thrombotic Thrombocytopenic Purpura
Reg. codes Name (References) Starting year Country Current situation Patient number
Reg.1 Oklahoma TTP-HUS Registry [34–36] 1989 US NA 434 (to 2015)
Reg.2* International Registry of recurrent and familial HUS/TTP [37–39] 1996 Italy Active 1200 (to 2016)
Reg.3* French Registry of aHUS in children [40] 2005 France Active 375 (to 2013)
Reg.4* Italian Registry of Hemolytic Uremic Syndrome [41, 42] 2005 Italy Active NA
Reg.5 International Registry and biorepository for TMA [31, 43] 2007 US Inactive NA
Reg.6* TTP/TMA Registry [44] 2011 Australia Active NA
Reg.7 German STEC-HUS Registry [45, 46] 2011 Germany NA 631(to 2012)
Reg.8* Atypical Hemolytic-Uremic Syndrome Registry [30, 47] 2012 US Active 852 (to 2019)
Reg.9* Turkish pediatric aHUS Registry [20, 48] 2013 Turkey Active 146 (to 2017)
Reg.10 TMA Registry of North America (TRNA) [33] 2013 US NA NA
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combination of two research projects in Hamburg and 
Hanover with the association of an IT company. An 
English version of the registry is now available, enabling 
other European countries to register patients with HUS 
[46].
Registry 8: Atypical HUS registry is a global, multi-
center registry system of patients with aHUS developed 
by the National Institute of Health (NIH). This system is 
the product of collaboration among universities around 
the world and the American Lexicon Pharmaceuticals 
[30].
Registry 9: Turkish pediatric aHUS registry is a national 
web-based registry system similar to (but not included 
in) the global aHUS registry, which the Faculty of Hac-
ettepe of University has implemented to enroll children 
with aHUS in pediatric nephrology hospitals in Turkey 
[20].
Registry 10: TMA Registry of North America (TRNA) 
was set up to overcome the limitations of research about 
rare TMA in the United States and to identify these 
patients for study at four US university centers (Colum-
bia, Duke, Alabama in Birmingham, and Pennsylvania). It 
was decided to launch this program at the meeting of the 
American Society for Apheresis (ASFA) in 2013 [49].
Comparison of the registries
Table  2 indicates the similarities and differences among 
the selected registries.
Table 2 shows that these 10 HUS registries were set up 
from 1989 to 2013, the oldest of which is in Oklahoma, 
USA. America and Europe each have 4 registries, and 
Australia and Asia each have one HUS registry. The geo-
graphical scope of the registries was diverse. Half of them 
were national (5 registries), 4 registries were also interna-
tional. The followings are the similarities and differences 
among each of the registries, based on the features:
1. The registry purposes were diverse, including clini-
cal purposes (to manage and improve patient care), 
research-based (to evaluate patients and better 
understand the disease, discovering unknown factors 
and identifying treatments and outcomes of the dis-
ease), and epidemiological goals (to determine out-
break of HUS). The majority of registries had clini-
cal purposes (Registries 1, 2, 4–10) [20, 31, 34, 38, 
39, 42, 45, 49, 51] followed by research-based regis-
tries (Registries 1–3, 5, 6, 8–10) [20, 31, 34, 38–40, 
49, 51]. Five registries also had epidemiological goals 
(Registries 4–7, 10) [31, 39, 42, 45, 49]. Out of the 10 
selected registries, only three followed all three types 
of purposes (Registries: 5, 6, 10) [31, 39, 49].
2. Except for one registry whose data was not found 
(Registry number 3) [40], the required data set in 
most of the registries [20, 31, 34, 38, 39, 42, 45, 49, 
51] included demographic data, medical and family 
history, para-clinical and diagnostic measures, treat-
ment and pharmacological data, complications, and 
short and long-term outcomes. Among these regis-
tries, one has added information about the effective-
ness of treatment and patient safety (Registry number 
8) [30], and four registries have considered biobank-
related data (Registries 1, 2, 5, 10) [31, 34, 38, 49].
3. Data quality assessment strategies included the 
monthly evaluation of data quality regarding the 
completeness and acceptability of data, and data 
audit (Registries 4 and 6) [39, 42], the participation 
of physicians (pediatric nephrologists) in collecting 
data, editing, and correcting data errors (Registries 8 
and 9) [20, 30], increasing the rate of data completion 
(Registry number 1) [34], following guidelines and 
data quality training (both, Registry number 6) [39], 
using specific data quality indicators (Registry num-
ber 10) [49], data errors tracking (Registry number 4) 
[42], and real-time evaluation of data at the time of 
its entry (Registry number 10) [49].
4. Inclusion or exclusion criteria of these registries were 
mainly defined based on the age of patients and the 
type of HUS (typical or atypical). Most registries 
included atypical HUS (Registries 1–6, 8, 9) [20, 31, 
34, 38–40, 42, 51] and all patients without any age 
limitation (Registries 1–4, 6–8) [30, 34, 38–40, 42, 
45]. Italian registry of HUS included both typical and 
atypical HUS (Registry number 4) [42]. The German 
HUS registry is also limited to the typical HUS (Reg-
istry number 7) [45]. Two registries exclude patients 
with the negative E. coli test (atypical HUS) (Regis-
tries 4 and 7) [42, 45].
5. In the most of compared registries (Registries 1, 3, 
5–10) [20, 30, 31, 34, 39, 40, 45, 49], the sub-special-
ists (pediatric nephrologists) themselves act as regis-
trars.
6. One registry collects data retrospectively (collecting 
data about previously-diagnosed patients) (Registry 
number 7) [45], four registries perform prospectively 
(collecting data to monitor the specific results and 
outcomes of the disease in the future) (Registries 3, 5, 
8, 10) [30, 31, 40, 49], and four other registries applies 
two methods (Registries 1,2, 4, 9) [20, 34, 38, 42].
7. The data resources of 9 registries include health care 
centers (such as specialized pediatric nephrology 
hospitals) (Registries 1, 2, 4–10) [20, 30, 31, 34, 38, 
39, 42, 45, 49]. Nephrology research centers (Regis-
tries 5 and 6) [31, 39] and diagnostic centers such as 
specialized nephrology laboratories (Registries 3 and 
4) [40, 42] also provide information to some of the 
HUS registries.
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Reg.2 [37–39] Reg.3 [40] Reg.4 [41, 42] Reg.5 [31, 43] Reg.6 [32, 44]
Geographical coverage Regional ✓ – – – – –
National – – ✓ ✓ – ✓
International – ✓ – – ✓ –
Purposes Clinical ✓ ✓ ✓ ✓ ✓ ✓
Research-based ✓ ✓ ✓ – ✓ ✓
Epidemiological-based – – – ✓ ✓ ✓
Data set Demographics ✓ ✓ – ✓ ✓ ✓
Clinical history ✓ ✓ – ✓ ✓ ✓
Paraclinical measures ✓ ✓ – ✓ ✓ ✓
Treatment ✓ ✓ – ✓ ✓ ✓
Outcomes ✓ ✓ – ✓ ✓ ✓
Biological samples – ✓ – – ✓ –
Patient evaluation (safety/
drug efficacy)
– – – – – –
Data quality assessment 
strategy
Completion of data ✓ – – – – –
Physician’s participation in 
data quality control
– – – – – –
Following data quality 
guidelines
– – – – – ✓
Using of data quality indica-
tors
– – – – – –
Evaluating and auditing data 
quality
– – – ✓ – ✓
Training courses on data 
quality
– – – – – ✓
Data errors tracking – – – ✓ – –
Real-time evaluation of data 
at the time of its entry
– – – – – –
Inclusion criteria Atypical HUS ✓ ✓ ✓ ✓ ✓ ✓
Typical UHS – – – ✓ – –
Children ✓ ✓ ✓ ✓ ✓ ✓
All ages ✓ ✓ ✓ ✓ – ✓
Exclusion criteria Atypical HUS – – – * – –
Typical UHS ✓ – ✓ – – –
Adults – – – – ✓ –
Registrars Physicians (nephrologists) ✓ – ✓ – ✓ ✓
Data collection Retrospective ✓ ✓ – ✓ – –
Prospective ✓ ✓ ✓ ✓ ✓ –
Data sources Healthcare centers ✓ ✓ –** ✓ ✓ ✓
Diagnostic centers – – ✓ ✓ – –
Research centers – – – – ✓ ✓
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Discussion
RDRs can be used to increase the knowledge about rare 
diseases and provide the samples to conduct the stud-
ies on the treatments and the quality of care for rare 
diseases [30]. However, lack of an executive plan, up-to-
date documented strategy, clear measurable purposes, 
and evaluation framework may result in the inconsistent 
registries [53]. We found that multiple HUS registries 
have different and distinguishable features which can be 
learned to develop other registries, as discussed below.
*With negative E. coli test
**No further information was found regarding data sources of this registry
HUS: Hemolytic Uremic Syndrome; Reg: Registry
Table 2 (continued)
Reg.7 [45, 46] Reg.8 [4, 
30, 47, 51, 
52]




Geographical coverage Regional – – – – 1
National – – ✓ ✓ 5
International ✓ ✓ – – 4
Purposes Clinical ✓ ✓ ✓ ✓ 9
Research-based – ✓ ✓ ✓ 8
Epidemiological-based ✓ – – ✓ 5
Data set Demographics ✓ ✓ ✓ ✓ 9
Clinical history ✓ ✓ ✓ ✓ 9
Paraclinical measures ✓ ✓ ✓ ✓ 9
Treatment ✓ ✓ ✓ ✓ 9
Outcomes ✓ ✓ ✓ ✓ 9
Biological samples – – – ✓ 4
Patient evaluation (safety/drug efficacy) – ✓ – – 1
Data quality assessment strategy Completion of data – – – – 1
Physician’s participation in data quality control – ✓ ✓ – 2
Following data quality guidelines – – – – 1
Using of data quality indicators – – – ✓ 1
Evaluating and auditing data quality – – – – 2
Training courses on data quality – – – – 1
Data errors tracking – – – – 1
Real-time evaluation of data at the time of its entry – – – ✓ 1
Inclusion criteria Atypical HUS – ✓ ✓ – 8
Typical UHS ✓ – – – 2
Children ✓ ✓ ✓ – 9
All ages ✓ ✓ – – 7
Exclusion criteria Atypical HUS * – – – 2
Typical UHS – ✓ – – 3
Adults – – ✓ – 2
Registrars Physicians (nephrologists) ✓ ✓ ✓ ✓ 8
Data collection Retrospective ✓ – ✓ – 5
Prospective – ✓ ✓ ✓ 8
Data sources Healthcare centers ✓ ✓ ✓ ✓ 9
Diagnostic centers – – – – 2
Research centers – – – – 2
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Purposes of HUS registries
By the rapid increase in the implementation of RDRs, 
the purposes of these systems have also become very 
diverse, from the management of patient clinical data 
to epidemiological and research purposes [16]. The spe-
cific purposes of RDR usually include identifying patients 
in families (due to being hereditary of most of the rare 
diseases) and identifying the course and evolution of 
disease, specific risks and outcomes, and supporting 
research (especially in the genetic field) as well as eval-
uation of drugs and treatments. In general, due to the 
knowledge gap in this field, the scope and purposes of 
RDRs are often wider than the other registries [19].
The purposes of the most HUS registries include opti-
mal management and treatment of patients [32, 35, 36, 
54], genetic evaluations in patients with HUS [20, 31, 37–
40, 43, 48], and collection of HUS epidemiological data in 
different populations [31, 32, 41–43]. Consequently, due 
to the rarity of HUS, it seems that considering all three 
types of clinical, epidemiological, and research purposes 
to implement these registries is necessary. Woodward, 
et  al. [30], in their study suggested that the purposes of 
HUS registry should include increasing knowledge about 
the disease, measuring the quality of HUS care, evaluat-
ing drug safety and other treatments which addresses 
both clinical and research aspects. Due to the lack of 
knowledge in the field of HUS management, research 
needs, and the lack of patient samples for research on this 
disease, it is recommended that specialists implement 
HUS registries with three aspects of clinical, research, 
and epidemiological purposes and meet these goals by 
establishing national or international systems to cover a 
large population.
Inclusion and exclusion criteria
Depending on the registry purposes, inclusion criteria 
can be very extensive or limited but often include demo-
graphic characteristics (e.g., patients’ age), diagnosis, 
treatment, laboratory tests, or diagnostic methods [55]. 
Most non-rare and common diseases have a clearer and 
more developed classification and diagnostic criteria 
than rare diseases (such as HUS) [19]. Therefore, it is 
very important to determine one or more specific inclu-
sion criteria for RDRs, such as HUS registries because 
it should be possible to detect all differential diagnoses 
through these criteria and enter exactly HUS patients.
Due to Vesely et  al. [36], the Oklahoma Registry 
includes any patients with HUS or TTP at any age who 
are candidates for PEX, and the registry only excludes 
children with STEC-HUS that received conservative 
treatments. This makes it easy to identify and record the 
majority of HUS patients in the Oklahoma population. 
On the one hand, such a criterion is proper for maxi-
mum coverage of HUS patients because various factors 
affect the course of the syndrome, (aHUS especially), 
such as the age of onset, the severity of complications, 
and response to treatment [38]. Therefore, these patients 
may show different manifestations and not be recognized 
using a specific criterion. On the other hand, this crite-
rion may lead to the entry of non-HUS patients who are 
wrongly candidates for PEX. Therefore, many HUS reg-
istries consider typical or atypical types of HUS (due to 
the presence or absence of Shiga toxin-producing E. 
coli (STEC)) along with the patient’s age (children, or 
all ages) as their inclusion criteria because these criteria 
can be easily checked and confirmed by diagnostic and 
laboratory tests. Therefore, due to the rarity of HUS and 
the scattered patients, and the need to implement multi-
center registries, it is recommended to use accurate and 
confirmable inclusion criteria such as a triad of throm-
bocytopenia, microangiopathic hemolytic anemia, and 
acute renal injury, type of syndrome, and the patient’s age 
for case finding and patient enrollment, so that its data 
can be comparable.
Minimum data set
The data elements of a registry should be limited and 
based on the purposes for which the registry is imple-
mented [25]. Data expansion usually occurs over time, 
but a useful way to select the mandatory data elements 
and optional ones (data elements that are useful but 
unnecessary). Thus, the minimum set of important data 
on the RDRs includes key patient data (such as demo-
graphic data), family history and disease-related data 
including history and course of the disease (and other 
clinical data such as medical history, para-clinical and 
diagnostic procedures, treatment plans and prescribed 
drugs, short-term and long-term side effects or out-
comes), data on the prevalence and distribution of the 
disease [19]. Moreover, patient’s status (e.g., alive, dead, 
loss to follow-up or opted-out), care pathway (date of 
the initial encounter to the specialized center), research-
related data (e.g., agreement or consent for reuse of 
patient’s data and receiving a biological sample for 
research purposes), and patient’s disability in accordance 
with International Classification of Functioning and Dis-
ability (ICF) are also suggested by European Commission 
Joint Research Centre for RDRs [56].
Managers of HUS registries also need these data sets, 
which exist in current HUS registries. Some researchers, 
such as Metjian et al. [49], stated that biological samples-
related data should also be recorded to facilitate future 
research in addition to the mentioned data sets. These 
data are needed to address research challenges and short-
ages of biological research samples, especially to identify 
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the relationship among genetic factors (by storing DNA 
and RNA samples) and incidence of HUS. In this case, by 
connecting multiple registries to a centralized bioreposi-
tory or biobank, more samples can be provided to under-
stand the disease course and the outcomes of patients 
[19].
Furthermore, Licht et  al. [4] stated that in their HUS 
registry, data on treatment efficacy and patient safety in 
response to the new drugs such as Ecu was added to the 
registry by comparing outcomes in different groups of 
patients. Moreover, this type of data is very effective to 
evaluate the effectiveness of various treatments of HUS. 
Therefore, the applicants for the HUS registry imple-
mentation are recommended to pay special attention to 
collect data related to the biological samples of patients 
(if necessary) and the safety and efficacy of drugs. Based 
on these findings, the proposed minimum data set for an 
HUS registry is presented in Table 3.
Data sources
If RDRs collect data from multiple data sources, the 
results of these systems will be more effective [57]. 
Furthermore, the best approach for implementing RDRs 
is a collaborative approach in which multinational and 
multi-institutional stakeholders combine resources [19, 
22]. Because of the non-outpatient nature of HUS, most 
of its data sources are nephrology (or pediatric neph-
rology) centers and hospitals. As stated by Woodward 
et  al. [30]. In the French aHUS registry, patients are 
also identified from French Reference Laboratory for 
registration, so laboratories may also be one of the data 
sources for the HUS registry [40]. However, laboratory 
centers alone are not complete sources for providing 
HUS data, because laboratories are not usually set up 
specifically to assess HUS or other pediatric nephrol-
ogy diseases and do not have comprehensive informa-
tion in this regard. Therefore, it seems that to develop 
HUS registries, communication with a set of healthcare 
centers, diagnostic and nephrology research centers is 
necessary. On the other hand, registries may need to 
integrate data from different sources [55]; therefore, the 
possibility of using the Electronic Health Record (EHR) 
is very helpful because it facilitates the process of case 
findings and completing patient records or follow-ups 
from different data sources.
Table 3 Proposed MDS for HUS registries
ADAMTS13: a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; ANA: Antinuclear antibody; DNA: Deoxyribonucleic Acid; E. coli: 
Escherichia coli; Ecu: Eculizumab; HUS: Hemolytic Uremic Syndrome; MRI: Magnetic Resonance Imaging; PEX: Plasma Exchange
Data group Data elements
Demographic and current episode data Patient identity: first name, last name, date and place of birth, place of residence, age, sex
Other patient data: weight, height, body mass index, race
Encounter summary such as final diagnosis, residual symptoms (e.g., neurologic, cardiac, renal, bleeding)
Data related to the patient care center and the referring physicians and centers
Medical and family history History of the HUS, risk factors and causes of the disease such as infections, systemic diseases, drugs used 
concomitantly with the disease, history of kidney transplantation, family history, time from diagnosis to 
patient registration, age of onset, co-morbidities (e.g. hypertension, malignancy, etc.),
Signs and symptoms (clinical/laboratory) Clinical: diarrhea (bloody or non-bloody), vomiting, nausea, abdominal pain, fever, number of days of onset 
of symptoms at the time of admission, time course of the acute illness, headache or dizziness, high blood 
pressure, paleness, lethargy
Laboratory (at admission and discharge): Hematology, biochemistry, immunology (such as ANA) tests, urine 
analysis (creatinine, urea, and blood levels in urine), urine culture, stool culture (to detect E. coli), genetic 
tests such as Complement factors (B, H, I), C3, C4, ADAMTS13, and direct antiglobulin test (direct Coombs)
Para-clinical measures Types of imaging of different parts of the body (ultrasound, MRI, etc.) and results
Therapeutic and pharmaceutical data Drugs: Ecu (number, the date of the first dose, and continuation of PEX after the start of Ecu), Rituximab, 
Antibiotics, Steroids, Anticoagulants, Coagulants, Immunoglobulins, Corticosteroids
Therapeutic measures: Plasma injections, PEX (date of first PEX, number of PEX), serum creatinine
Complications Complications of drugs, therapeutic or diagnostic measures (during hospitalization)
Efficacy and safety data for treatments, for example, meningococcal infections, sepsis, other serious infec-
tions, and death after Ecu or other medications
Short and long-term outcomes Severe hypertension, renal and neurological dysfunction (with severity), recurrence of the disease, Slurred 
speech, Personality changes, Visual impairment, Seizures, Coma, Length of hospital stay, Problems with 
concentration, memory, and fatigue, Depression, Systemic lupus erythematosus, Hypertension, Diabetes 
mellitus, Hemorrhage, Sepsis, Cognitive dysfunctions, Death (date and cause), Splenectomy, Hemodialysis, 
Peritoneal dialysis, Kidney or liver transplantation
Data about biological samples Plasma, urine, DNA, and umbilical cord (with sample details, date of sample collection, type of treatment, 
and laboratory values of patients on the date of sample collection)
Page 9 of 13Lazem et al. Orphanet J Rare Dis          (2021) 16:240  
Data collection method
HUS registries apply various methods for data collection. 
To collect comprehensive data on the disease course, 
the data should be collected through the interview with 
patients and receiving their previous information or 
reviewing the medical records of patients diagnosed 
(before launching the registry (retrospective) and also by 
collecting data over time and tracking the change of their 
symptoms or conditions (prospective). In their study, 
Kielstein et  al. [45] stated that the data were collected 
retrospectively in the German HUS registry. In the other 
HUS registry, most data collection was prospective with 
a focus on data collection during patient visits. However, 
the global aHUS registry collects data both retrospec-
tively and prospectively from pediatric nephrology cent-
ers [30], which maximizes the comprehensiveness of data 
related to before and after the disease.
Retrospective data collection can lead to missing data 
related to etiology, underlying diseases, family history of 
HUS, outcomes, and follow-ups because patient infor-
mation may not be available before the registry is set up. 
On the other hand, just being prospective also prevents 
previously diagnosed patients from being registered, and 
due to the rarity of the HUS, this leads to the loss of many 
cases. Therefore, HUS researchers who intend to set up a 
registry are recommended to use both retrospective and 
prospective methods, considering the feasibility of data 
collection and prioritization of key variables for data col-
lection from existing sources, current format, and limita-
tions of information sources [58].
Registry data quality control program
Assuring data quality is one of the most important fea-
tures to design and maintain rare disease registries [22]. 
Moreover, HUS registries should develop a specific pro-
gram and framework to evaluate and assure data quality.
Licht et  al. [4] indicate physicians’ increased partici-
pation in collecting, editing and correcting data errors 
to increase data quality and optimize the results of 
global aHUS registry. Another HUS registry applies the 
monthly evaluation of data quality due to the acceptabil-
ity, completeness, and compatibility with the main data 
of patients [41, 42], and uses these information for pre-
vention, identification, and correction of data errors reg-
ularly. Therefore, managers of HUS registries are advised 
to use a combination of methods to ensure data quality.
One of these methods is using coded data and classi-
fication systems, especially the use of Orphanet classifi-
cation, definitions for recording or reporting particular 
data items due to internationally agreed-upon guidelines 
(especially in multi-center registries). Other methods 
also include determining the quality indicators [59, 60], 
such as determining the percentage of missed data [61, 
62], comparing re-abstracted data with the main data 
from the data source [61], auditing the case-finding pro-
cess, and case reporting [63] in registry centers over time, 
data audit with continuous feedback [59, 64] by data 
quality supervisors, data error correction at data entry, 
automatic data validation [64, 65] and warnings about 
mandatory data elements [65, 66].
Since HUS registries are mainly multicenter, setting 
up a data usage agreement between participant centers 
and countries will help determine the ownership of data 
and result in more participation and registration of HUS 
cases.
Registrars
Because of this disease’s sub-specialization nature, pedi-
atric nephrologists act as a registrar in most of the exist-
ing registries. Woodward et al. [30] noted that in all HUS 
registry participant centers, pediatric nephrologists are 
responsible to enter the information of patients into the 
registry system because it is better to collect and enter 
data by personnel who are directly involved in the treat-
ment and diagnosis of this disease [45]. Since physicians 
and specialists are busy, enforcing them to enter data is 
very challenging [29]. Therefore, to facilitate this task, it 
is recommended that the interoperability between the 
registry software and other information systems such as 
electronic health record systems (EHRs) [67, 68] should 
be considered to import all types of data from these sys-
tems to the registry software. Furthermore, issuing data 
quality certificates can motivate physicians to participate 
in a registry system to be increased [65].
Due to the findings of study, the learning framework to 
implement HUS registries is presented in Fig. 1. This fig-
ure highlights the most important features to implement 
HUS registry, including purpose formulation, accurate 
inclusion/exclusion criteria, proper minimum data set, 
data sources, appropriate methods for data collection, 
and data quality control, as well as hiring knowledgeable 
registrars.
Limitations
This study has some limitations. The comparison of reg-
istries was limited to the resources available. Some of the 
required information about the registries was incom-
plete. In these cases, we contacted their managers; how-
ever, this information was not completely obtained.
Conclusion
This comparative study on selected HUS registries 
and their similarities and differences indicates that to 
develop and implement an HUS registry, a set of impor-
tant features should be considered: 1. Formulation of 
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Fig. 1 The suggested framework for implementing HUS registries
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comprehensive purposes on all three aspects of clinical, 
research, and epidemiology of HUS; 2. Developing appro-
priate inclusion criteria such as HUS diagnostic triad, 
determining typical or atypical HUS, and patient’s age, 
3. Developing an appropriate MDS; 4. Communication 
with different data sources, including healthcare centers 
(hospitals), diagnostic or nephrology research centers; 
5. Data quality assurance uses various methods such as 
using agreed international coding and classification sys-
tems, using data quality evaluation indicators, case find-
ing auditing, and data validation by the quality control 
supervisor or automatically with continuous feedback; 
and 7. Increased participation of nephrologists to enter 
data. By identifying and applying these features, manag-
ers and researchers can have more successful planning 
for implementing an HUS registry.
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